Home Use of an Artificial Beta Cell in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The feasibility, safety, and efficacy of prolonged use of an artificial beta cell (closed-loop insulin-delivery system) in the home setting have not been established. METHODS: In two multicenter, crossover, randomized, controlled studies conducted under free-living home conditions, we compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The closed-loop system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the closed-loop system for a 12-week period and sensor-augmented pump therapy (control) for a similar period. The primary end point was the proportion of time that the glucose level was between 70 mg and 180 mg per deciliter for adults and between 70 mg and 145 mg per deciliter for children and adolescents. RESULTS: Among adults, the proportion of time that the glucose level was in the target range was 11.0 percentage points (95% confidence interval [CI], 8.1 to 13.8) greater with the use of the closed-loop system day and night than with control therapy (P<0.001). The mean glucose level was lower during the closed-loop phase than during the control phase (difference, -11 mg per deciliter; 95% CI, -17 to -6; P<0.001), as were the area under the curve for the period when the glucose level was less than 63 mg per deciliter (39% lower; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0.5 to -0.1; P=0.002). Among children and adolescents, the proportion of time with the nighttime glucose level in the target range was higher during the closed-loop phase than during the control phase (by 24.7 percentage points; 95% CI, 20.6 to 28.7; P<0.001), and the mean nighttime glucose level was lower (difference, -29 mg per deciliter; 95% CI, -39 to -20; P<0.001). The area under the curve for the period in which the day-and-night glucose levels were less than 63 mg per deciliter was lower by 42% (95% CI, 4 to 65; P=0.03). Three severe hypoglycemic episodes occurred during the closed-loop phase when the closed-loop system was not in use. CONCLUSIONS: Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and, in adults, resulted in a lower glycated hemoglobin level. (Funded by the JDRF and others; AP@home04 and APCam08 ClinicalTrials.gov numbers, NCT01961622 and NCT01778348.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Medtronic 780G, 113,114 CamAPS FX, 115,116 and Diabeloop 117 received CE mark for use in European countries;”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [115]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 3×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 2×
“Hyperglycemia related to infusion-set occlusion 0 6 (18) 4 (12) 0 0 2 (8) 0 0”
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Wood, J. R., Miller, K. M., Maahs, D. M., Beck, R. W., DiMeglio, L. A., Libman, I. M., Quinn, M., Tamborlane, W. V., Woerner, S. E., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1959 · Cited by 415
Ly, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411
McKnight, J. A., Wild, S. H., Lamb, M. J. E., Cooper, M. N., Jones, T. W., Davis, E. A., Hofer, S., Fritsch, M., Schober, E., Svensson, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12676 · Cited by 343 · cited 6×
“Knee-joint arthralgia 0 1 (3) 0 0 0 0 0 0”
InfluentialClosed-loop insulin delivery from bench to clinical practice
Hovorka, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.32 · Cited by 342 · cited 1×
“Gastroenteritis 0 2 (6) 3 (9) 0 0 0 0 0”
Self-citation
Cited by
Items 301–400 of 454
A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes
Galderisi, A., & Sherr, J. L. (2019) · Pediatric Annals · doi:10.3928/19382359-20190725-03 · Cited by 8
The counterregulatory response to hypoglycaemia in the pig
Gradel, A. K. J., Kildegaard, J., Ludvigsen, T. P., Porsgaard, T., Schou‐Pedersen, A. M. V., Fels, J. J., Lykkesfeldt, J., & Refsgaard, H. H. F. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13422 · Cited by 8
Ishibashi, R., Baba, Y., Kakinuma, K., Takasaki, A., Hiraga, C., Harama, T., Yamamoto, T., Nakamura, S., Koshizaka, M., Maezawa, Y., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00971-2 · Cited by 8
“Treatment with a closed-loop pump that can automatically adjust according to blood glucose levels is being implemented [9, 10].”
BackgroundRuan, Y., Thabit, H., Leelarathna, L., Hartnell, S., Wilinska, M. E., Tauschmann, M., Dellweg, S., Benesch, C., Mader, J. K., Holzer, M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12956 · Cited by 8
“cipants with type 1 diabetes and conducted in free-living home settings.(2) Participants were randomly assigned to receive 12 weeks of automated closed-loop insulin delivery first and sensor-augmented pump therapy (open-loop) second, or vice versa applying rapid-acting insulin analogue, aspart or lispro, to follow the…”
MethodSelf-citationShi, D., Dassau, E., & Doyle, F. J. (2018) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc.2018.8619675 · Cited by 9
“outpatient clinical trials [1], [2] and also in the first US Food and Drug Administration (FDA) approved commercial hybrid AP system in the US [3].”
BackgroundClosed loop systems in type 1 diabetes
Waugh, N. R., Adler, A., Craigie, I., & Omer, T. (2018) · BMJ · doi:10.1136/bmj.k1613 · Cited by 10
Wang, Y.-Y., Ying, H., Fang, T. I. A. N., Qian, X., & Zhou, Z.-F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308202 · Cited by 10
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
Thabit, H., Mubita, W., Rubio, J., Karuppan, M., Schofield, J. D., Wilinska, M. E., Hovorka, R., & Leelarathna, L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14942 · Cited by 7
Self-citationRenard, É., Tubiana‐Rufi, N., Chaillous, L., Bonnemaison, É., Hanaire, H. P., Bismuth, É., Joubert, M., Coutant, R., Schaepelynck, P., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.002 · Cited by 13
Buschur, E., Reedy, J., Berget, C., Barnard, J. G., Garcetti, R., Nease, E., Bartholomew, A. B. C., Johnson, C. A., Driscoll, K. A., Dungan, K. M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.005 · Cited by 7
The artificial pancreas—ready for prime time?
DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30008-6 · Cited by 9
Les enjeux de la sécurité des objets connectés et applications de santé
Allaert, F., Mäzen, N.-J., Legrand, L., & Quantin, C. (2017) · Journal de gestion et d économie médicales · doi:10.3917/jgem.165.0311 · Cited by 7
Feasibility of large experimental animal models in testing novel therapeutic strategies for diabetes
Nagaya, M., Hasegawa, K., Uchikura, A., Nakano, K., Watanabe, M., Umeyama, K., Matsunari, H., Osafune, K., Kobayashi, E., Nakauchi, H., et al. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.306 · Cited by 7
de Jong, L. A., Li, X., Emamipour, S., van der Werf, S., Postma, M. J., van Dijk, P. R., & Feenstra, T. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01388-6 · Cited by 6
Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes
Tauschmann, M., & Hovorka, R. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360866 · Cited by 6
“Depending on control algorithm and the population, mean overnight glucose is lower [29,31,34,36,38], similar [27,32,35,37] or slightly elevated [28,33] than during control therapy.”
BackgroundMethodSelf-citationReiterer, F., Reiter, M., del Re, L., Christensen, M. B., & Nørgaard, K. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818770694 · Cited by 7
Optimizing a Hybrid Closed Loop System in Type 1 Diabetes: A Case Report
Petrovski, G., Khalaf, F. A., Hussain, K., & Campbell, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0473-6 · Cited by 6
AI in Healthcare: Implications for Family Medicine and Primary Care
Wojda, T. R., Hoffman, C. A., Jackson, J., Conti, T., & Maier, J. (2023) · Artificial intelligence · doi:10.5772/intechopen.111498 · Cited by 7
Quirós, C., Bertachi, A. H., Giménez, M., Biagi, L., Viaplana, J., Viñals, C., Vehí, J., Conget, I., & Bondía, J. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.12.004 · Cited by 8
The Minimed™ 670G Hybrid Automated Insulin Delivery System: Setting The Right Expectations
Leelarathna, L., & Thabit, H. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0242 · Cited by 6
Self-citationKaur, R. J., Deshpande, S., Pinsker, J. E., Gilliam, W. P., MCCRADY-SPITZER, S. K., Zaniletti, I., Desjardins, D., Church, M. M., Doyle, F. J., Kremers, W. K., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0436 · Cited by 7
Ongoing Debate About Models for Artificial Pancreas Systems and In Silico Studies
Forlenza, G. P. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0038 · Cited by 6
Plasma Insulin Cognizant Predictive Control for Artificial Pancreas
Rashid, M. M., Hajizadeh, I., & Çınar, A. (2018) · Proceedings of the ... American Control Conference/Proceedings of the American Control Conference · doi:10.23919/acc.2018.8431587 · Cited by 5
Ogishi, K., Osaki, T., Mimura, H., Hashimoto, I., Morimoto, Y., Miki, N., & Takeuchi, S. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115490 · Cited by 5
Cystic Fibrosis–Related Diabetes
Prentice, B. J., Hameed, S., Ooi, C. Y., Verge, C. F., & Widger, J. (2017) · InTech eBooks · doi:10.5772/66452 · Cited by 5
Pharmacological aspects of closed loop insulin delivery for type 1 diabetes
Uduku, C. N., & Oliver, N. S. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.006 · Cited by 5
A Hybrid Closed-Loop Insulin Delivery System for the Treatment of Type 1 Diabetes
Foerster, V., & Severn, M. (2016) · Europe PMC (PubMed Central) · Cited by 5
Improving Diabetes Care with Technology and Information Management.
Muegge, B. D., & Tobin, G. S. (2016) · Europe PMC (PubMed Central) · Cited by 7
Cai, D., Liu, W., Zhang, W., Wang, J., Peng, L., Ji, L., & Shi, D. (2022) · Control Engineering Practice · doi:10.1016/j.conengprac.2022.105338 · Cited by 5
The Future of the Artificial Pancreas
Thabit, H., & Hovorka, R. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0297 · Cited by 6
Self-citationFabris, C., Flanagan, D., Bennett, C., Batista, A. F. M. B., Oliveri, M. C., & Gonder-Frederick, L. A. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0003 · Cited by 5
Roy, M., & Jamwal, M. (2022) · International conference on public health and well-being · doi:10.32789/publichealth.2021.1008 · Cited by 4
Wang, Y.-Y., Ying, H., Tian, F., Qian, X., Zhou, Z.-F., & Zhou, C.-C. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2024-0098 · Cited by 4
Use of intraperitoneal insulin delivery for artificial pancreas
Renard, É., Farret, A., & Place, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00014-4 · Cited by 5
Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges
Bhagi, M., Kaur, J., Dhar, A., & Bhat, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010287216240324050651 · Cited by 4
Jose Medina Pestana, MD, PhD, FRCS
Medina-Pestana, J. O. (2015) · Transplantation · doi:10.1097/tp.0000000000001041 · Cited by 4
Glucagon Control Strategies for the Bi-hormonal Artificial Pancreas
Jones, R. W. (2019) · IEEE Conference on Industrial Electronics and Applications (ICIEA) · doi:10.1109/iciea.2019.8833900 · Cited by 4
“Both uni- and bi-hormonal AP systems have been shown to not only reduce glycaemic variation within type 1 diabetes subjects but also reduce the frequency of hypoglycaemic events when compared with conventional insulin pump therapy, for example see [10, 11].”
BackgroundNordheim, E., Lindahl, J. P., Carlsen, R. K., Åsberg, A., Birkeland, K. I., Horneland, R., Boye, B., Scholz, H., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-20-0519 · Cited by 4
Beyond A1C: A Practical Approach to Interpreting and Optimizing Continuous Glucose Data in Youth
Al-Gadi, I., Menon, S., Lyons, S. K., & DeSalvo, D. J. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0095 · Cited by 4
Dénes-Fazakas, L., Fazakas, G. D., Eigner, G., Kovács, L., & Szilágyi, L. S. (2024) · IEEE International Symposium on Applied Computational Intelligence and Informatics (SACI) · doi:10.1109/saci60582.2024.10619866 · Cited by 8
Pharmacotherapy options for pediatric diabetes
Marcovecchio, M. L., & Chiarelli, F. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000504 · Cited by 4
Existing and Potential Applications of Glucose Prediction Models
Georga, E. I., Fotiadis, D. I., & Tigas, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804831-3.00009-1 · Cited by 3
Leelarathna, L., Thabit, H., Hartnell, S., Willinska, M. E., Dellweg, S., Benesch, C., Mader, J. K., Holzer, M., Kojzar, H., Evans, M. L., et al. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816654715 · Cited by 3
“We observed substantially improved glycemic control following addition of real-time continuous glucose monitoring (CGM) combined with structured education during run-in period in a study investigating prolonged use of day and night closed-loop.(1) This was an open-label, 3-center, multinational randomized 2-period cro…”
Self-citationUse of advanced technology for the treatment of type 1 diabetes in pregnancy
Geerts, I., & Benhalima, K. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102026 · Cited by 3
Auf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-119492 · Cited by 3
Role of Whole Organ Pancreas Transplantation in the Day of Bioartificial and Artificial Pancreas
Manay, P., Turgeon, N. A., & Axelrod, D. A. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00300-3 · Cited by 4
Management of tandem occlusions in patients who receive rtPA
Smetana, K. S., Zakeri, A., Dolia, J. N., Huttinger, A., May, C. C., Youssef, P. P., Gross, B. A., & Nimjee, S. M. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02510-7 · Cited by 3
Peters, C. J., Annan, F., Hindmarsh, P. C., & Thompson, R. J. (2021) · Paediatrics and Child Health · doi:10.1016/j.paed.2021.01.002 · Cited by 3
Self-citationHybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes
Service, C. H. T. A. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.50 · Cited by 4
Adaptive and Individualized Artificial Pancreas for Precision Management of Type 1 Diabetes
Toffanin, C., Cobelli, C., & Magni, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_15 · Cited by 4
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Torres‐Castaño, A., Rivero‐Santana, A., Perestelo‐Pérez, L., Duarte‐Díaz, A., Sacks, A. A., Ramos‐García, V., Álvarez‐Pérez, Y., Wägner, A. M., Rigla, M., & Serrano‐Aguilar, P. (2022) · Applied Sciences · doi:10.3390/app122010262 · Cited by 4
Technological Innovations in Type 1 Diabetes Mellitus Management: A Narrative Review
Gunatilake, S. S. C. (2024) · Sri Lanka Journal of Diabetes Endocrinology and Metabolism · doi:10.4038/sjdem.v15i1.7534 · Cited by 5
Thabit, H., Lim, J. Z. M., Wilinska, M. E., Fullwood, C., Hovorka, R., & Leelarathna, L. (2025) · Diabetic Medicine · doi:10.1111/dme.70122 · Cited by 3
Self-citationSensor Life and Overnight Closed Loop: A Randomized Clinical Trial
Tauschmann, M., Allen, J. M., Wilinska, M. E., Ruan, Y., Thabit, H., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816678631 · Cited by 3
“We hypothesized that this is related to the robustness of our model predictive algorithm, which mitigates against sensor inaccuracy and has been safely and effectively used in a range of populations and settings including pregnant women, adults, adolescents and children in unsupervised home application.(10,22,23,24) T…”
BackgroundSelf-citationJin, S. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.190 · Cited by 3
“The results of major clinical trials of artificial pancreas technologies are summarized in Table 1 [13,15-17].”
BackgroundTargeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Stratégie de transplantation chez les patients diabétiques de type 1
Buron, F., Badet, L., & Morélon, E. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.006 · Cited by 3
New technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Insulin Pumps and Artificial Pancreas
Taleb, N., Gingras, V., & RABASA-LHORET, R. P. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65407-7 · Cited by 3
Modelado y simulación de tecnologías para el tratamiento de la diabetes
Rosales, N. (2020) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/97299 · Cited by 7
Recent advances and perspectives in novel insulin release systems
Barkhordari, S., Samandari, S. S., Abdouss, M., & Pourmadadi, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106500 · Cited by 2
How Important Is a Closed‐Loop Artificial Pancreas?
Foltyński, P. (2018) · Artificial Organs · doi:10.1111/aor.13338 · Cited by 2
Lv, D., Garcia‐Tirado, J., & Fabris, C. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1803019 · Cited by 2
Variation of glucose time in range in type 1 diabetes
Hansen, K. W., & Bibby, B. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.379 · Cited by 2
Closed-Loop Visceral Bioelectronics Therapies
Raczkowska, M. N., & Thakor, N. V. (2023) · Handbook of Neuroengineering · doi:10.1007/978-981-16-5540-1_118 · Cited by 2
Forlenza, G. P., Tabatabai, I., & Lewis, D. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0073 · Cited by 3
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ktfr5698 · Cited by 2
Self-citationModellig of adrenaline counterregulatory action during hypoglycaemia in Type 1 Diabetes
Moscardo, V., Rossetti, P., Ampudia-Blasco, F. J., & Bondia, J. (2016) · 2016 IEEE Conference on Control Applications (CCA) · doi:10.1109/cca.2016.7587868 · Cited by 2
“It has been demonstrated that the automated system increases the percentage of time in euglycaemic range and improves the average blood glucose levels, although with similar hypoglycaemia than open-loop therapy [2].”
BackgroundData as Transformational: Constrained and Liberated Bodies in an ‘Artificial Pancreas’ Study
Farrington, C. (2017) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-349-95235-9_6 · Cited by 2
Sensor‐augmented pump therapy: review of new NICE diagnostic guidance
Raj, S., & Chakera, A. J. (2016) · Practical Diabetes · doi:10.1002/pdi.1999 · Cited by 2
Dreyer, M. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0112-7 · Cited by 2
Artificial Pancreas: A Concise Review
Rhee, S. Y., Han, S. W., & Woo, J. (2017) · Journal of Korean Diabetes · doi:10.4093/jkd.2017.18.3.141 · Cited by 2
“…et al. 2015 [32] 10 (T1DM) 7.0 5 nights Close loop system (DiAs) 80~140 mg/dL, overnight (23:00~07:00 h) 22.3% higher (54.5% vs. 32.2%; P < 0.001) Thabit et al. 2015 [33] 40 (T1DM) 8.0 4 wk Close loop system (FlorenceD2A) 3.9~8.0 mmol/L 18.5% higher (P < 0.001), overnight Nimri et al. 2014 [34]…”
InfluentialA new feedback predictive control approach for processes with time delay in the manipulated variable
Rollins, D. K., & Mei, Y. (2018) · Chemical Engineering Research and Design · doi:10.1016/j.cherd.2018.06.018 · Cited by 2
Free-living use of artificial pancreas for children with type 1 diabetes: systematic review
Dovč, K., Mutlu, G. Y., Philippov, Y. I., Лаптев, Д. Н., Patrakeeva, E. M., Chernilova, L. O., Zalevskaya, A. G., Shestakova, M. V., & Battelino, T. (2018) · Diabetes Mellitus · doi:10.14341/dm9714 · Cited by 2
Blanc, R., Ugalde, H. M. R., Benhamou, P., Charpentier, G., Franc, S., Huneker, E., Villeneuve, E., & Doron, M. (2019) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2019.8857170 · Cited by 2
“Notably, one study [10] showed very positive results on adults and children in an outpatient setting for 12 weeks.”
BackgroundKattner, N., Carlsson, P., & Scott, W. E. (2021) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2021.100046 · Cited by 1
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
Twenty years of progress in type 1 diabetes mellitus
Kay, T. W. H., & Couper, J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01177-x · Cited by 1
“The APCam and AP@home consortia conducted two cross-over trials, one in adults (day and night) and one in children and adolescents (overnight only), which were analysed together 2 .”
Griffin, T. P., Hagan, J., Chauhan, R., Crabtree, T. S. J., Ackroyd, D., Elliott, J., Narendran, P., Bawlchhim, Z., Wilmot, E. G., Hadjiconstantinou, M., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113084 · Cited by 1
Sidki, A., HIGHTON, P. J., O’Mahoney, L. L., & Wilkinson, T. J. (2026) · Diabetic Medicine · doi:10.1111/dme.70210 · Cited by 1
Continuous subcutaneous insulin infusion in patients with type 1 disease
Meetoo, D. D., Wong, L., & Fatani, T. (2017) · British Journal of Healthcare Management · doi:10.12968/bjhc.2017.23.7.313 · Cited by 1
Bloomgarden, Z. T. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.02.001 · Cited by 1
Closed-loop control in type 1 diabetes
Buckingham, B. A., & Ly, T. T. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00015-2 · Cited by 1
Psychosoziale Aspekte aktueller Diabetestechnologien
Lange, K. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0159-5 · Cited by 1
“Unbeschwert mit Diabetes zu leben und dabei automatisch zuverlässig die richtige Insulindosis zu erhalten, ohne dass es zu akut bedrohlichen Hypoglykämien oder langfristig schädigenden Hyperglykämien kommt, ist der Wunsch vieler Betroffener und das Ziel aktueller Forschungsansätze zu einem artifiziellen Pankreas (AP,…”
BackgroundFuture Drug Treatments for Type 1 Diabetes
Sherr, J. L., Cengiz, E., Name, M. A. V., WEINZIMER, S. A., & Tamborlane, W. V. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch66 · Cited by 1
Highlights from the Diabetes UK Professional Conference 2017
David, F. (2017) · Practical Diabetes · doi:10.1002/pdi.2095 · Cited by 1
Enlarging the loop: closed-loop insulin delivery for type 1 diabetes
Galderisi, A., & Sherr, J. L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32329-8 · Cited by 3
Establishing the incidence and timing of hypoglycemia at a residential diabetes camp
Mann, E. A., Lunos, S. A., Carrel, E., Omann, T., Halper, A., Kogler, A., Miller, B. S., Sunni, M., Bellin, M. D., & Nathan, B. M. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.04.003 · Cited by 1
Gamad, N., Shafiq, N., & Malhotra, S. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136569 · Cited by 1
BITAPS: A Mobile-Computing Assisted Artificial Pancreas Systems Control Platform
Yang, X., Mou, Z., He, L., Zhang, X., & Shi, D. (2020) · Youth Academic Annual Conference of Chinese Association of Automation (YAC) · doi:10.1109/yac51587.2020.9337587 · Cited by 1
L'insulinothérapie au xxie siècle : une symphonie de plus en plus harmonieuse
Benhamou, P., Hanaire, H. P., & Renard, É. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(21)00179-6 · Cited by 1
First World Consensus Conference on Pancreas Transplantation
Boggi, U., Vistoli, F., & Marchetti, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_86 · Cited by 1
Event-Triggered Adaptive Disturbance Rejection for Artificial Pancreas
Shi, D., Huang, Y., Wang, J., & Shi, L. (2021) · Studies in systems, decision and control · doi:10.1007/978-981-16-0293-1_9 · Cited by 1
Zulewski, H. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.11.001 · Cited by 1
Use of liraglutide in type 1 diabetes: implications for management
Simmons, D. S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00459-3
The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes
Levy, B. L., McCann, T. W., & Finan, J. A. D. A. (2016) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2016.12.01.18
Stoica, R. A. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0015
“Going further in the future, he presented the results of his 12-week randomized control study [3], in which he compared a closed-loop system with sensor-augmented pump therapy in 58”
BackgroundClosed-Loop-Therapie im Alltag mit Typ-1-Diabetes erfolgreich
Forst, T. M. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0753-4
Role of Dual-Hormone Closed-Loop Delivery System in the Future
Bally, L., Thabit, H., & Hovorka, R. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0259
Self-citation
Metadata
- Authors
- Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., Mader, J. K., Holzer, M., Kojzar, H., Exall, J., Yong, J., Pichierri, J., Barnard, K. D., Kollman, C., Cheng, P., Hindmarsh, P. C., Campbell, F. M., Arnolds, S., Pieber, T. R., Evans, M. L., Dunger, D. B., & Hovorka, R.
- Affiliations
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Profil Institute for Metabolic Research (DE)
- Medical University of Graz (AT)
- Leeds Teaching Hospitals NHS Trust (GB)
- University College Hospital (GB)
- Bournemouth University (GB)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2129-2140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4697362
- OpenAlex
- W2332531077
- Cited by
- 450
- References
- 29
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 23 · 2023: 29 · 2022: 31 · 2021: 43 · 2020: 34 · 2019: 49 · 2018: 71 · 2017: 71 · 2016: 68 · 2015: 10
- FWCI
- 63.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Funders
- Wellcome Trust (100574, 100574/Z/12/Z)
- National Institute for Health and Care Research (NF-SI-0508-10274, NF-SI-0513-10012, CAMBRC-2012-1)
- Swansea University
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, artificial beta cell, sensor-augmented pump therapy, glycemic variability, HbA1c, children and adolescents, adults, continuous glucose monitoring, insulin pump therapy, free-living conditions, hypoglycemia risk reduction, glycemic control
- MeSH terms
- Adolescent, Adult, Algorithms, Child, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Infusion Pumps, Implantable, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.